Stocks · Healthcare · Biotechnology
Benitec Biopharma Inc. BNTC
$8.98 -6.26% Close, Oct 2, 2026 · NASDAQ · Market cap $308.5M
Next earnings report: Nov 13, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 28.6% in a year.
- Over the past year the stock returned -35.9%, behind the S&P 500 by 51.0 percentage points.
- The stock is 46% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 42%
- Accruals (lower is better)Top 21%
- Interest coverBottom 26%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 44%
- Free-cash-flow yieldBottom 48%
- EBITDA / enterprise valueBottom 17%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 31%
- 6-month returnBottom 26%
- 1-year return vs S&P 500Bottom 18%
- Distance from 52-week highBottom 33%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 39%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 31%
- Upside to consensus price targetTop 30%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 45%
- Maximum drawdown, 3 yearsTop 19%
- Beta vs S&P 500 (lower is better)Top 43%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | — | Bottom 2% | |
| Return on invested capital | -28.8% | — | Bottom 42% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -15.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +12.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -21.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -33.59%
- Shareholder yield
- -33.59%
- Share count change, 1 year
- +28.6%
- Share count change, 3-year CAGR
- +92.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Sep 14, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +9.2%
- Average 2-day reaction, last 8
- +2.2%
- Positive 20 days after report
- 5 of 7
Analysts
- Consensus price target
- $21.00
- Target vs current price
- +133.9%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 88%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Sep 14, 2026 | +1.6% | -0.9% | -9.6% | — | — |
| May 14, 2026 | +11.1% | +1.7% | -5.7% | -5.2% | +18.3% |
| Feb 12, 2026 | -13.0% | -2.7% | -7.0% | +4.0% | +5.4% |
| Nov 14, 2025 | +37.1% | +0.1% | -0.1% | -8.9% | -11.4% |
| Sep 22, 2025 | -50.0% | +0.4% | +1.9% | +16.4% | -9.4% |
| May 14, 2025 | +33.3% | +3.0% | +5.7% | +25.6% | -10.5% |
| Feb 14, 2025 | +64.0% | +16.0% | +16.5% | +54.3% | +35.5% |
| Nov 14, 2024 | +12.7% | -0.4% | +2.1% | +18.3% | -2.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Sep 14, 2026 | -$0.26 | -$0.26 | +1.6% | — |
| May 14, 2026 | -$0.24 | -$0.27 | +11.1% | — |
| Feb 12, 2026 | -$0.26 | -$0.23 | -13.0% | — |
| Nov 14, 2025 | -$0.22 | -$0.35 | +37.1% | — |
| Sep 22, 2025 | -$0.42 | -$0.28 | -50.0% | $556,000 |
| May 14, 2025 | -$0.24 | -$0.36 | +33.3% | — |
| Feb 14, 2025 | -$0.36 | -$1.00 | +64.0% | — |
| Nov 14, 2024 | -$0.48 | -$0.55 | +12.7% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -5.54% | — | — | Bottom 48% |
| Earnings yield | -10.91% | — | — | Bottom 44% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.9%
- 200-day average slope (20 days)
- -1.7%
- Distance from 50-day average
- -24.8%
- Distance from 200-day average
- -24.6%
- RSI (14)
- 27.5
- Relative volume
- 0.86×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 53.4%
- Volatility vs own 5-year history
- 12th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.99
- Correlation with S&P 500
- 0.25
- Current drawdown from 1-year high
- -45.6%
- Maximum drawdown, 3 years
- -46.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 23, 2021 | Aug 8, 2023 | -98.8% | 598 days | Not yet recovered |
| Sep 30, 2020 | Mar 4, 2021 | -58.8% | 106 days | 13 days (Mar 23, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $308.5M
- EPS, diluted (TTM)
- -$0.98
- Revenue (TTM)
- $0
- 52-week range
- $8.92 – $16.76
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Revenue | $73,000 | $75,000 | $0 | $0 | $0 |
| Gross profit | $64,000 | $75,000 | -$343,000 | -$396,000 | -$481,000 |
| Operating income | -$17.9M | -$19.1M | -$22.5M | -$41.8M | -$51.2M |
| Net income | -$18.2M | -$19.6M | -$21.8M | -$37.9M | -$45.5M |
| EPS (diluted) | -$19.31 | -$14.12 | -$2.68 | -$1.05 | -$0.98 |
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $556,000 | $0 | $0 | $0 | $0 |
| Net income | -$5.1M | -$9.6M | -$14.5M | -$16.1M | -$9.0M | -$11.8M | -$11.9M | -$12.8M |
| EPS (diluted) | -$0.48 | -$0.33 | -$0.38 | -$0.39 | -$0.21 | -$0.26 | -$0.24 | -$0.27 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Operating cash flow | -$15.9M | -$18.0M | -$19.4M | -$23.6M | -$16.5M |
| Capital expenditure | -$13,000 | -$1,000 | -$179,000 | -$18,000 | -$105,000 |
| Free cash flow | -$15.9M | -$18.0M | -$19.6M | -$23.6M | -$16.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $17.9M | $70.9M | $70.5M | $99.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $180.0M
- Total assets
- $182.6M
- Total liabilities
- $5.6M
- Total debt
- $762,000
- Net debt
- -$179.2M
- Shareholders’ equity
- $177.0M
As of Jun 30, 2026 (filed Sep 14, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jun 1, 2018 | $0.00 | Jun 8, 2018 |
Short interest
- Shares sold short
- 2,186,142
- Days to cover
- 19.97
- Change vs previous report
- -1.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 26, 2023
- 1-for-17
- Apr 15, 2020
- 2-for-3
- Nov 18, 2019
- 1-for-10
- May 2, 2018
- 1,019-for-1,000
- Jun 16, 2015
- 1-for-4